Latest Content

How to Individually Tailor Myelofibrosis Treatment Options

September 16th 2025, 7:00pm

By Ryan Scott

Article

Dr. Prithviraj Bose explains how doctors tailor myelofibrosis treatments and how patients can work with their care teams to navigate options.

A Day in the Life of a Breast Cancer Survivor

September 16th 2025, 5:00pm

By Bonnie Annis

Article

Since being diagnosed with breast cancer, my life has drastically changed. Time has helped each day become more precious and has caused me to become more grateful.

Jakafi for Myelofibrosis Associated With Skin Cancer, Shingles Risk

September 16th 2025, 4:00pm

By Alex Biese

Article

For patients with myelofibrosis, there is a risk of non-melanoma skin cancer or shingles among patients who received long-term treatment with Jakafi.

FDA Grants Designation to Investigational Drug for Head and Neck Cancer

September 16th 2025, 3:00pm

By Ryan Scott

Article

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck squamous cell carcinoma.

Can Anemia or Bleeding Be a Sign of Gastrointestinal Stromal Tumors?

September 16th 2025, 1:00pm

By Dr. Rosario Ligresti

Video

Dr. Rosario Ligresti explained that while many GISTs are found incidentally, larger tumors may cause anemia, bleeding or swallowing issues.

Thanking My Support System From My Cancer Journey

September 15th 2025, 9:00pm

By Carla Deschamps

Article

Five years after being diagnosed with colon cancer, I would like to share how my support system continues to play a role in my life after active treatment.

Ibtrozi May Address Unmet Needs In ROS1-Positive Non-Small Cell Lung Cancer

September 15th 2025, 8:00pm

By Dr. Geoffrey Liu

Video

Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer.

Actively Recruiting Trials for Lung, Biliary, AML and Small Cell Cancer

September 15th 2025, 7:00pm

By Spencer Feldman

Article

Early trial results report progression-free survival and response rates for ateganosine, spevatamig, Annamycin and pumitamig; studies are currently enrolling.

The Lessons of the Woods

September 15th 2025, 5:00pm

By Georgia Hurst

Article

Walking the woods shows me how to release fear, grief, and expectations, trusting that letting go nourishes growth, resilience and life’s next season.

Prostatectomy Not Guaranteed to be Curative in Prostate Cancer

September 15th 2025, 4:00pm

By Alex Biese

Article

For men with prostate cancer, radical prostatectomy, or surgical removal of the prostate, isn’t guaranteed to be curative, as one expert explained.

FDA Grants Breakthrough Status to Raludotatug Deruxtecan in Ovarian Cancer

September 15th 2025, 3:00pm

By Spencer Feldman

Article

The FDA granted breakthrough therapy designation to R-DXd for adults with CDH6-expressing platinum-resistant ovarian, peritoneal or fallopian tube cancers.

Patient Advocate and Caregiver Shares Advocacy Journey in KRAS Cancers

September 15th 2025, 1:00pm

By Dr. Joshua K. Sabari

Video

Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.

The Seasons of Life: A Metaphor for Identity and Legacy

September 14th 2025, 6:00pm

By Andy Winnegar

Article

The changing seasons offer a profound metaphor for the circle of life, an idea that resonates deeply with me.

Real-World Study Finds Benefit of Lutathera in Patients With Lung NETs

September 14th 2025, 2:00pm

By Ashley Chan

Article

Lutathera demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors.

Tepmetko Associated With Frequent Side Effects for Some With NSCLC

September 13th 2025, 6:00pm

By Jax DiEugenio

Article

For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.